City of Hope PANXEON Pancreatic Cancer Blood Test
Analysis based on 17 articles · First reported Sep 16, 2026 · Last updated Sep 17, 2026
The study highlights a potential breakthrough in early cancer detection, which could boost sentiment for diagnostic and biotech companies developing liquid biopsy platforms. Commercialization prospects remain uncertain pending further validation, but the involvement of Biocartis and its option on PANXEON points to potential upside for that company.
Researchers led by City of Hope developed an investigational liquid biopsy called PANXEON that could detect pancreatic cancer at its earliest, potentially curable stages. The large international study, published in Nature Medicine, tested the blood test in nearly 1,800 patients across the United States, Europe and Asia. PANXEON analyzes three pancreatic cancer biomarkers - circulating microRNAs, exosomal microRNAs and the protein CA19-9 - and uses artificial intelligence to combine them into a single composite risk score. The test correctly identified stage 1 and 2 pancreatic cancer 87% of the time, with a false-positive rate of 3% in low-risk groups and 16% in high-risk groups. It also detected high-grade dysplasia, a precancerous condition often considered stage 0 pancreatic cancer, more than 64% of the time, potentially enabling intervention before invasive cancer develops. Senior author Ajay Goel, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope, said the findings represent progress toward finding pancreatic cancer before symptoms appear. The study was supported by the United States — National Institutes of Health, the United States — National Cancer Institute and the Italian Association for Cancer Research. Ajay Goel is a paid consultant to Biocartis, which holds an option to acquire the rights to PANXEON. City of Hope's affiliated organizations include the Translational Genomics Research Institute and AccessHope. Additional large-scale prospective studies are warranted to validate the test's utility.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard